NeuroOne Medical Technologies Corp 2025年季度报告

Item 1.Legal Proceedings35Item 1A.Risk Factors35 NeuroOne Medical Technologies CorporationNotes to Condensed Financial Statements NOTE 1 – Description of Business and Basis of Presentation NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is a medical technologycompany focused on the development and commercialization of thin film electrode for continuous electroencephalogram (“cEEG”)and stereoelectrocencephalography (“sEEG”) recording, monitoring, ablation, drug delivery and brain stimulation solutions to The Company has received 510(k) clearance from the United States (“U.S.”) Food and Drug Administration (“FDA”) for three of itsdevices: (i) its Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days, (ii) its Evo®sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for therecording, monitoring, and stimulation of electrical signals at the subsurface level of the brain; and (iii) its OneRF ablation system for The Company is based in Eden Prairie, Minnesota. Global Economic Conditions Generally, worldwide economic conditions remain uncertain, particularly due to the conflicts between Russia and Ukraine and in theMiddle East, disruptions in the banking system and financial markets, and increased inflation. The general economic and capitalmarket conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’saccess to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising The Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and othereconomic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts inUkraine and the Middle East, disruptions in the banking system and financial markets, and steps taken by governments and central Basis of presentation The accompanying unaudited condensed financial statements have been prepared by the Company, pursuant to the rules andregulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normallyincluded in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have beencondensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly thefinancial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the NeuroOne Medical Technologies CorporationNotes to Condensed Financial Statements NOTE 2 – Liquidity The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a goingconcern. The Company has incurred losses since inception, negative cash flows from operations since inception, and an accumulateddeficit of $75.5million as of March 31, 2025. To date, the Company’s revenues have not been sufficient to cover its full operatingcosts, and as such, it has been dependent on funding operations through the issuance of debt and sale of equity securities whichpreviously resulted in substantial doubt regarding the Company's ability to continue as a going concern. As of March 31, 2025, theCompany had $1.3million in cash and cash equivalents and, as disclosed in “Note 13 – Subsequent Events,” the Company received In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its developmentactivities. The Company’s future operating activities, coupled with its plans to raise capital or issue debt financing, may provideadditional liquidity in the future; however, these actions are not solely within the control of the Company and the Company is unable NOTE 3 – Summary of Significant Accounting Policies Management’s Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions thataffect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial Segment Information Operating segments are components of an enterprise for which separate financial information is available and are evaluated regularlyby the Company’s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company’schief operating decision maker is its Chief Executive Officer. The Company’s Chief Executive Officer views the Company’s Cash and Cash Equivalents The Company considers all highly liquid investments with an original contractual m